Proton therapy represents a major advance in contemporary radiotherapy and will eventually replace the conventional radiation.

VIDEO Invitation to PTCOG 55 in Prague and to Proton Therapy Center Czech HERE.

Dear Colleagues,

on behalf of the Proton Therapy Center Czech in Prague, we invite you to attend the 55th Annual Conference PTCOG 55, taking place May 22-28, 2016. For most of us an annual conference is already a highly significant event but we would like to add several other incentives for visiting Prague in 2016.

Primarily, particle therapy is getting stronger round the world with the number of proton centres and patients under treatment growing. This simultaneously increases the clinical experience and public awareness. We are convinced that PTCOG 55 will provide many new, predominantly technical and clinical results that will become a turning point in this field and will further accelerate development and acceptance of particle therapy in radiation oncology. To participate in this will be both a great experience and an opportunity.

Today data sharing is possible anywhere and with anyone in the world. However, personal contact, networking and discussion with industry partners can inspire further ideas and projects. We are looking forward to fruitful discussion about the presented results and the future of further advances in our field and co-operation.

Particle therapy is an exceptionally complex field, based on the knowledge and efforts of many generations of scientists, predominantly doctors and physicists. From this point of view, Prague is the most suitable place for such a meeting. The prestige Charles University was founded in 1348 by Charles IV, the emperor of the Holy Roman Empire, and many important figures in the history of physics and medicine worked in Prague, for example, physicists Tycho de Brahe and Albert Einstein and in the field of medicine, Jan Evangelista Purkyně.

Prague was established 1,000 years ago and for the most of its history has been a centre of European education and culture. We are proud of this legacy and it will be an honour to continue this tradition with your visit. Besides that, the city is beautiful....

It will be our pleasure to welcome you to Prague at PTCOG 55 in May, 2016.

Iva Taťounová                Jiří Kubeš                                       Vladimír Vondráček
Director PTC                  Medical Director PTC                    Chief Physicist PTC


The possibility of using proton beams for radiotherapy was discovered in the forties shortly after the initiation of cyclotron activities. The scientific work discussing their usage in medicine was published in the Journal of Radiology in June 1946 by Robert Wilson. This physician contributed to the development of the cyclotron in Donner’s (later Lawrence's) laboratory at the University of California.

He discovered the possibility of administering high doses of radiation to small target areas while
preserving surrounding tissue. Based on his work scientists in the Harvard cyclotron laboratory and the
Lawrence laboratory in Berkeley modified their research cyclotrons so that they could be used for treatment. The first patients with intracranial lesions were irradiated by the end of the fifties. Later on, the therapy was commenced in various other locations around the world.

Initially, in the first years, the idea of radiation using protons was not positively considered by radiation
oncologists. This was caused by limited possibilities due to the use of a narrow beam with a relatively low energy level. Furthermore, the treatment was performed using very expensive devices: devices primarily used for research. The clinical results obtained under such conditions were so promising that they resulted in the development of special devices for radiotherapy, so today there is the possibility to treat deeply localised tumors located virtually anywhere within the body.

Only in the eighties was an accelerator and gantry system developed that could be used solely for the
clinical irradiation of patients. The costs of therapy significantly reduced as the device was only used for
this purpose. Clinical experience, very promising therapeutic results and the development of computer technology enabling precise control of beams within the body of the patient, enabled the certification agency FDA (the Food and Drug Administration) in the USA to approve protons for clinical practice in 1992.

The first clinical center developed at that time (a large cyclotron site with four treatment rooms for
clinical use, capable of treating 100 patients a day) directly within a hospital was in the Loma Linda University Medical Center (LLUMC) in Los Angeles. This was considered a breakthrough in the treatment of malignant tumors using modern radiotherapy. The center in Loma Linda was followed by centers in Chiba (1994) and Kashiwa (1998) in Japan, the former using carbon ions (800 MeV) and the latter a proton beam (235 MeV).

There is 41 operating proton therapy centers today (Source: PTCOG) and a new center opens every month or two.

Proton is expected to eventually replace the traditional methods of radiotherapy in the future and thus, holds immense market potential, as stated by the Research and Markets – leading source for market data. More...